Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel Adjei

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2016
Can sub-Saharan Africa feed itself?Martin K van Ittersum, Lenny G J van Bussel, Joost Wolf, et al.
Lancet (London, England)|September 22, 2009
Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trialsJohn J Aponte, David Schellenberg, Andrea Egan, et al.
Vaccine|March 21, 2020
Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trialKwaku Poku Asante, Daniel Ansong, Seyram Kaali, et al.
The Lancet. Infectious Diseases|May 9, 2024
Genotypic analysis of RTS,S/AS01<sub>E</sub> malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5-17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trialMichal Juraska, Angela M Early, Li Li, et al.
Medrxiv : the Preprint Server for Health Sciences|December 4, 2023
Baseline malaria infection status and RTS,S/AS01E malaria vaccine efficacyMichal Juraska, Angela M Early, Li Li, et al.
Vaccine|November 12, 2019
Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan AfricaLucas Otieno, Yolanda Guerra Mendoza, Samuel Adjei, et al.
The Lancet. Infectious Diseases|September 7, 2015
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialMichael T White, Robert Verity, Jamie T Griffin, et al.
Human Vaccines & Immunotherapeutics|April 24, 2019
Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan AfricaYolanda Guerra Mendoza, Elodie Garric, Amanda Leach, et al.
Malaria Journal|October 29, 2017
Longitudinal estimation of Plasmodium falciparum prevalence in relation to malaria prevention measures in six sub-Saharan African countriesChris Drakeley, Salim Abdulla, Selidji Todagbe Agnandji, et al.
Nature Communications|October 23, 2023
A genomic appraisal of invasive Salmonella Typhimurium and associated antibiotic resistance in sub-Saharan AfricaSandra Van Puyvelde, Tessa de Block, Sushmita Sridhar, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2016
Can sub-Saharan Africa feed itself?Martin K van Ittersum, Lenny G J van Bussel, Joost Wolf, et al.
Lancet (London, England)|September 22, 2009
Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trialsJohn J Aponte, David Schellenberg, Andrea Egan, et al.
Vaccine|March 21, 2020
Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trialKwaku Poku Asante, Daniel Ansong, Seyram Kaali, et al.
The Lancet. Infectious Diseases|May 9, 2024
Genotypic analysis of RTS,S/AS01<sub>E</sub> malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5-17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trialMichal Juraska, Angela M Early, Li Li, et al.
Medrxiv : the Preprint Server for Health Sciences|December 4, 2023
Baseline malaria infection status and RTS,S/AS01E malaria vaccine efficacyMichal Juraska, Angela M Early, Li Li, et al.
Vaccine|November 12, 2019
Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan AfricaLucas Otieno, Yolanda Guerra Mendoza, Samuel Adjei, et al.
The Lancet. Infectious Diseases|September 7, 2015
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialMichael T White, Robert Verity, Jamie T Griffin, et al.
Human Vaccines & Immunotherapeutics|April 24, 2019
Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan AfricaYolanda Guerra Mendoza, Elodie Garric, Amanda Leach, et al.
Malaria Journal|October 29, 2017
Longitudinal estimation of Plasmodium falciparum prevalence in relation to malaria prevention measures in six sub-Saharan African countriesChris Drakeley, Salim Abdulla, Selidji Todagbe Agnandji, et al.
Nature Communications|October 23, 2023
A genomic appraisal of invasive Salmonella Typhimurium and associated antibiotic resistance in sub-Saharan AfricaSandra Van Puyvelde, Tessa de Block, Sushmita Sridhar, et al.
Pageof 10